Compounds containing short amino alcohol chains and metal complexes thereof and applications thereof

By developing compounds containing short amino alcohol chains and Gd3+ complexes, the problems of uneven distribution and poor stability of gadolinium contrast agents in the body are solved, high relaxation and plasma stability are achieved, and the risk of adverse reactions is reduced. A safer magnetic resonance imaging solution.

CN118834263BActive Publication Date: 2024-12-03CHENGDU SHIBEIKANG BIOLOGICAL MEDICINE TECH CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411290090.2
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-09-14
Publication Date
2024-12-03
Estimated Expiration
2044-09-14

AI Technical Summary

Technical Problem

The existing gadolinium magnetic resonance imaging contrast agents are unevenly distributed in the body, have poor stability, and may lead to the risk of nephrotoxicity. They may release free Gd3+ after intravenous injection, resulting in adverse reactions.

Method used

Develop a metal complex formed by complexing a compound containing short amino alcohol chain with metal ions (such as Gd3+) with good solubility, relaxability and chemical stability as a magnetic resonance imaging contrast agent.

Benefits of technology

The complex exhibits excellent stability in plasma, avoids the release of free Gd3+, significantly improves imaging contrast, and reduces the risk of adverse reactions, providing a safer imaging solution.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118834263B_ABST
    Figure CN118834263B_ABST
Patent Text Reader

Abstract

The present invention discloses a compound containing a short amino alcohol chain and a metal complex thereof and application thereof, belonging to the field of medical imaging technology. The compound containing a short amino alcohol chain provided by the present invention is shown in the following formula. The compound containing a short amino alcohol chain provided by the present invention is used as a ligand to react with Gd 3+ The complex formed by complexation has high relaxivity and strong chelation stability, especially showing excellent chelation stability in plasma and good safety. 3+ The complex has potential clinical application prospects as a magnetic resonance imaging contrast agent. #imgabs0#
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of medical imaging, and specifically relates to a compound containing a short amino alcohol chain, a metal complex obtained by taking the compound as a ligand, and application of the metal complex in preparing a magnetic resonance imaging contrast agent. Background Art

[0002] Magnetic resonance imaging (MRI) is based on the energy transition of atomic nuclei with magnetic moments under the action of a magnetic field, and uses the magnetic resonance principle to image the difference in hydrogen nucleus density between different tissues of the human body. Due to the low sensitivity of MRI, contrast agents are needed to improve the imaging contrast between the lesion site and healthy tissue. Among them, MRI contrast agents containing paramagnetic and superparamagnetic metals are currently the most commonly used MRI contrast agents because they can obtain stronger signals and higher spatial resolution due to changes in proton relaxation time and increased relaxation rate.

[0003] Among them, gadolinium contrast agents (GBCA) are widely used in magnetic resonance imaging. The first gadolinium MRI contrast agent was a chelate of diethylenetriamine pentaacetic acid (DTPA) and Gd (III) (Gd-DTPA) developed by Schering, Germany. It can effectively shorten the spin-lattice relaxation time (T1) of tissues and is currently the most widely used MRI positive contrast agent. At present, the gadolinium contrast agents that have been approved for clinical use include: gadopentetate dimeglumine (Magnevist), gadoteric acid meglumine (Dotarem), gadoteridol (ProHance), gadodiamide (Omniscan), gadobutrol (Gadovist), gadoxetic acid (Primovist), gadobenate dimeglumine (MultiHance) and gadofosveset trisodium. With the exception of gadoxetic acid, gadobenate dimeglumine, and gadofosveset trisodium, GBCAs exhibit a strictly extracellular passive distribution in vivo and are excreted exclusively via the kidneys.

[0004] Currently used GBCAs still have various defects, such as high injection doses, low relaxivity, and the risk of nephrotoxicity caused by poor stability. Although gadolinium contrast agents are generally considered safe in clinical practice, some patients still experience adverse reactions, such as headaches, nausea, taste changes, or urticaria. Very few patients may develop anaphylactic shock or long-term nephrogenic systemic fibrosis. Some preclinical studies have shown that intravenous injection of gadolinium contrast agents can release free Gd 3 + , free Gd 3+ It can be rapidly distributed to the bones and liver, with a small amount of deposition. Therefore, the chelation stability of gadolinium contrast agents is a key factor to be considered during drug development.

[0005] An ideal GBCA needs to meet the following conditions: 1. exhibit high relaxivity; 2. show a favorable pharmacokinetic curve; 3. be completely excreted; 4. be chemically stable; 5. exhibit high water solubility; 6. provide the potential for significant dose reduction and be suitable for imaging of different body parts.

[0006] Based on the above background, the present invention develops a compound containing a short amino alcohol chain. The metal complex formed by using the compound as a ligand to complex with metal ions has the advantages of good solubility, high relaxivity, good chemical stability and plasma stability, and has broad clinical application prospects as a magnetic resonance imaging contrast agent. Summary of the invention

[0007] The first object of the present invention is to provide a compound containing a short amino alcohol chain; the second object of the present invention is to provide a metal complex, which is formed by complexing with metal ions using the compound containing a short amino alcohol chain as a ligand; the third object of the present invention is to provide a method for preparing the metal complex; the fourth object of the present invention is to provide a pharmaceutical composition; and another object of the present invention is to provide a use of the above-mentioned active substance in the preparation of a magnetic resonance imaging contrast agent.

[0008] The present invention includes the following technical solutions:

[0009] In the first aspect of the present invention, the present invention provides a compound containing a short amino alcohol chain as shown in Formula I, or an enantiomer thereof, or a diastereomer thereof, or a pharmaceutically acceptable salt thereof:

[0010]

[0011] (I)

[0012] wherein G is selected from hydrogen, deuterium, halogen, substituted or unsubstituted C1-C 12 Alkyl or cycloalkyl, substituted or unsubstituted C1-C 12 Alkoxy, substituted or unsubstituted C1-C 12 Alkylmercapto, substituted or unsubstituted C1-C 12 of alkylamino.

[0013] Preferably, G is -OCH3 or H.

[0014] R1, R2, R3 are independently selected from -COOH, carboxylate / salt, -P(O)(OH)2, R a -P(O)(OH)2, phosphate ester / salt, R a Selected from H or C1-C3 alkylene.

[0015] R 11A hydrogen atom or a group selected from:

[0016] C1-C6 alkyl, C3-C6 cycloalkyl, (C1-C2 alkoxy)-(C2-C3 alkyl)-, heterocyclic aryl and phenyl,

[0017] wherein the C1-C6 alkyl is optionally substituted identically or differently by a phenyl substituent, and the phenyl substituent is optionally substituted identically or differently 1, 2 or 3 times by a halogen atom or a group selected from the following:

[0018] C1-C3 alkyl, C1-C3 haloalkyl and C1-C3 alkoxy; and

[0019] The heterocyclic aryl and phenyl groups are optionally substituted 1, 2 or 3 times identically or differently by halogen atoms or groups selected from the following:

[0020] C1-C3 alkyl, C1-C3 haloalkyl and C1-C3 alkoxy.

[0021] Preferably, R 11 Selected from H.

[0022] L is selected from -C(R0)2-, wherein R0 is independently selected from a hydrogen atom, a deuterium atom, a trifluoromethyl group, a hydroxymethyl group, a mercaptomethyl group, a hydroxyalkyl group, a mercaptoalkyl group, an alkoxyalkyl group, a thioetheralkyl group, an aminoalkyl group, a substituted aminoalkyl group, a carboxyl group, an ester group, an amide group, a carboxylalkyl group, an ester group, an amide group, a phenyl group, a phenylalkyl group, an aromatic heterocyclic group, an aromatic heterocyclic group alkyl group, a heterocyclic group, a heterocyclic group alkyl group or a group selected from the following:

[0023] C1-C6 alkyl, C3-C6 cycloalkyl,

[0024] wherein the C1-C6 alkyl is optionally substituted identically or differently by a phenyl substituent, and the phenyl substituent is optionally substituted identically or differently 1, 2 or 3 times by a halogen atom or a group selected from the following:

[0025] Hydroxy, C1-C3 alkyl, C1-C3 haloalkyl and C1-C3 alkoxy; and

[0026] wherein the phenyl, phenylalkyl, aromatic heterocyclic group, aromatic heterocyclic group alkyl, heterocyclic group, heterocyclic group alkyl are optionally substituted 1, 2 or 3 times by halogen atoms or groups selected from the following groups:

[0027] Hydroxyl, C1-C3 alkyl, C1-C3 haloalkyl and C1-C3 alkoxy.

[0028] Preferably, R0 is independently selected from H, C1-C3 alkyl, C1-C3 hydroxyalkyl.

[0029] Y represents OH, NH2, -CO-NR b R c or -NR b -CO-R c , where R b , R c Each independently represents H or C1-C6 alkyl or C l -C6 hydroxyalkyl, and R b or R c At least one representative C l -C6 hydroxyalkyl.

[0030] Preferably, Y is -AB-R4, wherein A is selected from -CO-; B is selected from -N(R5)-, R5 is selected from H, C1-C3 alkyl, C1-C3 hydroxyalkyl; and R4 is selected from H or C1-C6 hydroxyalkyl.

[0031] K1-K8 are each independently selected from H, -(CH2) j -CH3 or (CH2) i -OH, wherein j is 0-8 and i is 1-8.

[0032] Preferably, K1-K8 are each independently selected from -H, C1-C6 alkyl, C1-C6 hydroxyalkyl.

[0033] The C1-C6 alkyl group described in the present invention is selected from any C1, C2, C3, C4, C5, C6 straight-chain or branched alkyl group known to those skilled in the art.

[0034] Preferably, the C1-C6 alkyl group includes but is not limited to -CH2-, -CH2-CH2-, -CH2-CH2-CH2-, -CH2-CH2-CH2-CH2-, -CH2-CH2-CH2-CH2-, -CH2-CH2-CH2-CH2-CH2-, -CH2-CH2-CH2-CH2-CH2-, -CH2-CH2-CH2-CH2-CH2-CH2-.

[0035] The C1-C6 hydroxyalkyl group of the present invention is selected from a C1, C2, C3, C4, C5, C6 straight or branched alkyl group containing one or more hydroxyl groups. l -C6 hydroxyalkyl groups include but are not limited to -CH2-CH2OH, -CHOH-CH2OH, -CH-(CH2OH)2, -(CH2) p -(CHOH) q -CH2OH, wherein p=1-3, q=1-4, and p+q=2-5, or -C-(CH2OH)3.

[0036] The C1-C3 alkyl group or C1-C3 hydroxyalkyl group described in the present invention is as defined above and will not be repeated here.

[0037] Preferably, the compound containing a short amino alcohol chain is selected from the structure shown in Formula II-1 or Formula II-2:

[0038] (Ⅱ-1),

[0039] (Ⅱ-2);

[0040] R0 is selected from H, C1-C2 alkyl, C1-C2 hydroxyalkyl;

[0041] R5 is selected from H, C1-C2 alkyl, C1-C2 hydroxyalkyl;

[0042] Specifically, the C1-C2 alkyl group is selected from -CH3 and -CH2-CH3; the C1-C2 hydroxyalkyl group is selected from -CH2OH and -CH2-CH2OH.

[0043] R4 is H or , wherein R6 and R7 are selected from H or -CH2OH, and m is selected from an integer between 0 and 4, specifically 0, 1, 2, 3, 4. When m is 0, it means that the -CHOH- group does not exist.

[0044] In one embodiment of the present invention, the compound containing a short amino alcohol chain is selected from any one of the structures shown in formula III-1a, formula III-1b, and formula III-1c:

[0045]

[0046] ;

[0047] In another embodiment of the present invention, the compound containing a short amino alcohol chain is as shown in Formula III-2a, Formula III-2b, and Formula III-2c:

[0048]

[0049] ;

[0050] In the above formula, m is selected from 0, 1, 2, 3 or 4. When m is 0, it means that the -CHOH- group does not exist.

[0051] R0 is selected from H, -CH3 or -CH2OH.

[0052] R5 is selected from H, -CH3 or -CH2-CH2OH.

[0053] R8, R9, R 10are each independently selected from H or -CH2OH, and R8, R9, R 10 At least one of them is -CH2OH; preferably, R8, R9, R 10 More preferably, R8, R9, R 10 All are -CH2OH.

[0054] In the most preferred embodiment of the present invention, the compound containing a short amino alcohol chain is selected from any one of the following structures:

[0055] , ,

[0056] , ,

[0057] , ,

[0058] , ,

[0059] , ,

[0060] , ,

[0061] , ,

[0062] , ,

[0063] , ,

[0064] , .

[0065] The short amino alcohol chain-containing compound of the present invention also includes its stereoisomers, tautomers, N-oxides, hydrates, solvates or mixtures thereof.

[0066] The short amino alcohol chain-containing compound of the present invention also includes a polymer formed by the above-mentioned short amino alcohol chain-containing compound, and the polymer is preferably a dimer, trimer or tetramer.

[0067] The short amino alcohol chain-containing compound of the present invention also includes a conjugate obtained by coupling the short amino alcohol chain-containing compound with any peptide, protein or monoclonal antibody via a bonding group.

[0068] The bonding groups include amino, hydroxyl, carboxyl, carbonyl, thiol, thioether and the like.

[0069] Common peptides in the art that can be coupled with the compound containing a short amino alcohol chain include, but are not limited to, ingr polypeptide, NGR polypeptide, Pasireotide, Triptorelin polypeptide, and Octreotide.

[0070] In the second aspect of the present invention, the present invention provides a metal complex, which is a complex of the compound containing a short amino alcohol chain as described in the first aspect of the present invention and a metal ion, wherein the metal is selected from paramagnetic metal ions or radioactive nuclide ions.

[0071] The paramagnetic metal ion is selected from Gd 3+ , Mn 2+ , Yb 3+ or Fe 3+ .

[0072] The radionuclide ions are selected from 99 Tc, 117 Sn, 111 In, 97 Such as 67 Ga, 89 Zr, 177 Lu, 47 Sc, 105 Rh, 188 Re, 60 Cu, 62 Cu, 64 Cu, 67 Cu, 90 Y. 159 Gd, 149 Pr or 166 Ho.

[0073] Preferably, the complex is a compound containing a short amino alcohol chain as described in the first aspect of the present invention and Gd 3+ of chelates.

[0074] Specifically, the metal complex has a structure shown in formula L-I:

[0075]

[0076] (L-Ⅰ)

[0077] In the formula, G, L, Y, K1-K8, R1, R2, R3, R 11 As described in the first aspect of the present invention.

[0078] Furthermore, the metal complex has the structure shown in Formula L-II-1 and Formula L-II-2:

[0079] ,

[0080] (L-Ⅱ-1) (L-Ⅱ-2)

[0081] R0, R4 and R5 in the formula are as described in the first aspect of the present invention.

[0082] In some embodiments of the present invention, the metal complex has the structure shown in formula L-III-1a, formula L-III-1b and formula L-III-1c:

[0083] ,

[0084] (L-Ⅲ-1a) (L-Ⅲ-1b)

[0085] ;

[0086] (L-Ⅲ-1c)

[0087] In other embodiments of the present invention, the metal complex has the structure shown in formula L-III-2a, formula L-III-2b and formula L-III-2c:

[0088] ,

[0089] (L-Ⅲ-2a) (L-Ⅲ-2b)

[0090] ;

[0091] (L-Ⅲ-2c)

[0092] In the formula, m, R0, R5, R8, R9, R 10 As described in the first aspect of the present invention.

[0093] In a specific embodiment of the present invention, the metal complex is selected from any of the following structural formulas:

[0094] , ,

[0095] , ,

[0096] , ,

[0097] , ,

[0098] , ,

[0099] , ,

[0100] , ,

[0101] , ,

[0102] , ,

[0103] , .

[0104] In the third aspect of the present invention, the present invention provides a method for preparing the metal complex, the method comprising:

[0105]

[0106] ;

[0107] In the formula, G, R0, R4 and R5 are as described in the first aspect of the present invention.

[0108] As shown in the above formula, compound M2 is dissolved in water, the pH is adjusted to 6, compound M1 and dioxane are added, HOBT and EDCI are added under stirring, the pH of the reaction solution is adjusted to 6, the reaction is carried out for 24 hours, and the mixture is concentrated under reduced pressure. An equal volume of ethanol and ether are added to disperse the solid, and the mixture is filtered and separated by reverse phase preparative chromatography to obtain metal complex M.

[0109] In the fourth aspect of the present invention, the present invention provides a pharmaceutical composition, which comprises the compound containing a short amino alcohol chain as described in the first aspect of the present invention or the metal complex as described in the second aspect of the present invention, and a pharmaceutically acceptable excipient or auxiliary agent.

[0110] The use of the pharmaceutically acceptable adjuvant or auxiliary agent depends on the specific composition and the specific administration method. The pharmaceutical composition of the present invention has various suitable formulations, including but not limited to lipid nanoparticles prepared by the compound containing a short amino alcohol chain or a metal complex.

[0111] In the fifth aspect of the present invention, the present invention provides a use of the compound containing a short amino alcohol chain as described in the first aspect of the present invention, the metal complex as described in the second aspect of the present invention or the pharmaceutical composition as described in the fourth aspect of the present invention in the preparation of a contrast agent for magnetic resonance imaging.

[0112] The compound containing a short amino alcohol chain provided by the present invention and Gd 3+ The formed complex has good solubility, high relaxivity and good pharmacokinetic characteristics. The present invention technicians unexpectedly found that the compound containing a short amino alcohol chain provided by the present invention as a ligand and Gd 3+ The complex formed by complexation has strong chelation stability, especially showing excellent stability in plasma, which solves the problem that conventional gadolinium contrast agents release free Gd after intravenous injection. 3+ to prevent patients from suffering from free Gd 3+ Adverse reactions occur. The compound containing short amino alcohol chains prepared by the present invention and Gd 3+ The complex has potential clinical application prospects as a magnetic resonance imaging contrast agent. DETAILED DESCRIPTION

[0113] The technical solutions in the embodiments of the present invention are described clearly and completely below. Obviously, the described embodiments are only some embodiments of the present invention, not all. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0114] Explanation of terms

[0115] The term "C1-C6 alkyl" refers to any straight chain or branched chain group of C1, C2, C3, C4, C5, C6 well known to those skilled in the art.

[0116] The term "C1-C6 hydroxyalkyl" refers to a C1, C2, C3, C4, C5, C6 straight or branched chain group containing one or more hydroxyl groups.

[0117] The term "pharmaceutically acceptable" means that the substance or composition must be compatible chemically and / or toxicologically with the other ingredients comprising the formulation and / or the mammal to be treated therewith.

[0118] The term "pharmaceutically acceptable excipients or adjuvants" may include any solvents, solid excipients, diluents or other liquid excipients, etc., suitable for a particular target dosage form.

[0119] The following is further described by specific examples. It should be understood that these examples are only used for more detailed description and should not be understood as limiting the present disclosure in any form.

[0120] The compound names corresponding to the English abbreviations described in the present invention are as follows:

[0121] HCl: hydrochloric acid

[0122] EDCI: 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride

[0123] HOBT: 1-Hydroxybenzotriazole

[0124] Gd2O3: Gadolinium oxide

[0125] The structures of the compounds in the embodiments of the present invention were determined by nuclear magnetic resonance ( 1 H-NMR) or liquid chromatography-mass spectrometry (LC-MS) for characterization. The "room temperature" in the present invention refers to 10-25°C.

[0126] G 3+ Preparation of complex

[0127] Example 1 Synthesis of Complex 1

[0128]

[0129] 0.88 g (9.7 mmol, 3.6 eq) of 3-amino-1,2-propanediol was dissolved in 50 ml of water, and the pH of the reaction solution was adjusted to 6 with 2N HCl. 2.34 g (2.7 mmol, 1 eq) of complex X and 40 ml of dioxane were added to the reaction solution. 1.57 g of HOBT (11.6 mmol, 4.3 eq) and 2.22 g of EDCI (11.6 mmol, 4.3 eq) were added under stirring, and the pH of the reaction solution was adjusted to 6. After reacting for 24 hours, the reaction solution was concentrated under reduced pressure to about 20 ml. 100 ml of ethanol and 100 ml of ether were added to the reaction bottle to disperse the solid, and the mixture was filtered and separated by reverse phase preparative chromatography to obtain 0.93 g (32%, 0.86 mmol) of complex 1 of Example 1 with a purity of 97.2%.

[0130] LC-MS(ESI+): m / z=1088.2(M+H) + .

[0131] Example 2 Synthesis of Complex 2

[0132]

[0133] The preparation method is the same as that of Example 1, except that 3-amino-1,2-propanediol in Example 1 is replaced with 2-aminoethanol to obtain Complex 2 of Example 2 with a purity of 97.8%.

[0134] LC-MS(ESI+): m / z=998.3(M+H) + .

[0135] Example 3 Synthesis of Complex 3

[0136]

[0137] The preparation method is the same as that of Example 1, except that 3-amino-1,2-propanediol in Example 1 is replaced with 2-amino-1,3-propanediol to obtain Complex 3 of Example 3 with a purity of 98.1%.

[0138] LC-MS(ESI+): m / z=1088.2(M+H) + .

[0139] Example 4 Synthesis of Complex 4

[0140]

[0141] The preparation method is the same as that of Example 1, except that 3-amino-1,2-propanediol in Example 1 is replaced with 3-(methylamino)-1,2-propanediol to obtain Complex 4 of Example 4 with a purity of 96.8%.

[0142] LC-MS(ESI+): m / z=1130.5(M+H) + .

[0143] Example 5 Synthesis of Complex 5

[0144]

[0145] The preparation method is the same as the preparation method of Example 1, except that 3-amino-1,2-propanediol in Example 1 is replaced with 2-amino-2-hydroxymethyl-1,3-propanediol to obtain Complex 5 of Example 5 with a purity of 97.8%.

[0146] LC-MS(ESI+): m / z=1178.3(M+H) + .

[0147] Example 6 Synthesis of Complex 8

[0148]

[0149] The preparation method is the same as that of Example 1, except that 3-amino-1,2-propanediol in Example 1 is replaced with glucosamine to obtain Complex 8 of Example 6 with a purity of 98.2%.

[0150] LC-MS(ESI+): m / z=1358.5(M+H)+ .

[0151] Example 7 Synthesis of Complex 9

[0152]

[0153] The preparation method is the same as the preparation method of Example 1, except that 3-amino-1,2-propanediol in Example 1 is replaced with 2-(2-hydroxyethylamino)-2-hydroxymethyl-1,3-propanediol to obtain complex 9 of Example 7 with a purity of 97.2%.

[0154] LC-MS(ESI+): m / z=1310.5(M+H) + .

[0155] Example 8 Synthesis of Complex 10

[0156]

[0157] The preparation method is the same as that of Example 1, except that the 3-amino-1,2-propanediol in Example 1 is replaced with aqueous ammonia to obtain the complex 10 of Example 8 with a purity of 96.2%.

[0158] LC-MS(ESI+): m / z=865.9(M+H) + .

[0159] Example 9 Synthesis of Complex 11

[0160]

[0161] The preparation method is the same as the preparation method of compound 1 in Example 1, except that complex X in Example 1 is replaced by complex Y, to obtain complex 11 in Example 9 with a purity of 97.2%.

[0162] LC-MS(ESI+): m / z=1058.2(M+H) + .

[0163] Example 10 Synthesis of Complex 12

[0164]

[0165] The preparation method is the same as the preparation method of compound 2 in Example 2, except that complex X in Example 2 is replaced by complex Y, to obtain complex 12 in Example 10 with a purity of 97.7%.

[0166] LC-MS(ESI+): m / z=968.2(M+H) + .

[0167] Example 11 Synthesis of Complex 13

[0168]

[0169] The preparation method is the same as the preparation method of compound 3 in Example 3, except that complex X in Example 3 is replaced by complex Y, to obtain complex 13 in Example 11 with a purity of 96.3%.

[0170] LC-MS(ESI+): m / z=1058.2(M+H) + .

[0171] Example 12 Synthesis of Complex 14

[0172] The preparation method is the same as the preparation method of compound 4 in Example 4, except that complex X in Example 4 is replaced by complex Y, to obtain complex 14 in Example 12 with a purity of 98.7%.

[0173] LC-MS(ESI+): m / z=1100.4(M+H) + .

[0174] Example 13 Synthesis of Complex 15

[0175]

[0176] The preparation method is the same as that of Example 5, except that the complex X in Example 5 is replaced by complex Y, to obtain complex 15 of Example 13 with a purity of 97.3%.

[0177] LC-MS(ESI+): m / z=1148.4(M+H) + .

[0178] Example 14 Synthesis of Complex 18

[0179]

[0180] The preparation method is the same as that of Example 6, except that the complex X in Example 6 is replaced by complex Y, to obtain complex 18 of Example 14 with a purity of 97.2%.

[0181] LC-MS(ESI+): m / z=1328.5(M+H) + .

[0182] Example 15 Synthesis of Complex 19

[0183]

[0184] The preparation method is the same as that of Example 7, except that the complex X in Example 7 is replaced by complex Y, to obtain complex 19 of Example 15 with a purity of 98.4%.

[0185] LC-MS(ESI+): m / z=1280.4(M+H) + .

[0186] Example 16 Synthesis of Complex 20

[0187]

[0188] The preparation method is the same as that of Example 8, except that the complex X in Example 8 is replaced by complex Y, to obtain the complex 20 of Example 16 with a purity of 96.4%.

[0189] LC-MS(ESI+): m / z=836.2(M+H) + .

[0190] Example 17 Synthesis of Complex X

[0191]

[0192] Synthesis of compound Int.2-3:

[0193] 64.00g (399.6mmol, 1eq) Int.2-1, 70.34g (419.6mmol, 1.05eq) Int.2-2, 64.79g HOBT (479.5mmol, 1.2eq), 91.92g EDCI (479.5mmol, 1.2eq) were added to 1.6L dichloromethane, and 206.58g DIEA (1598.4mmol, 4.0eq) was added at room temperature and stirred at room temperature for overnight reaction. After the reaction was completed, the concentrate was chromatographed by silica gel column to obtain 40.43g (37%, 147.9mmol) of the target compound Int.2-3 with a purity of 95.9%.

[0194] LC-MS(ESI+): m / z=274.5(M+H) + .

[0195] 1 H NMR (400 MHz, CDCl3)δ 3.91 (s, 2H), 3.26 (s, 2H), 1.41 (s, 18H).

[0196] Synthesis of compound Int.2:

[0197] 37.99g (139.0mmol, 1eq) Int.2-3 and 25.39g (166.8mmol, 1.2eq) DBU were added to 800ml tetrahydrofuran, and 55.32g (166.8mmol, 1.2eq) CBr4 was added under ice bath conditions to react for 2h. After the reaction was completed, 800ml of saturated ammonium chloride aqueous solution was added to quench the reaction, and the aqueous phase was extracted with 4L of dichloromethane, and the organic phase was collected, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The concentrate was chromatographed on a silica gel column to obtain 25.96g (53%, 73.7mmol) of the target compound Int.2 with a purity of 98.7%.

[0198] LC-MS(ESI+): m / z=353.3(M+H) + .

[0199] 1 H NMR (400 MHz, CDCl3)δ 4.96 (s, 1H), 3.98 (s, 2H), 1.41 (s, 9H), 1.39 (s, 9H).

[0200]

[0201] Synthesis of compound Int.3:

[0202] 4.65g (19.7mmol, 1eq) of Int.1 (synthesized by referring to J. Am. Chem. Soc. 2018, 140, 11, 3916–3928), 24.97g (70.9mmol, 3.6eq) of Int.2 and 10.89g (78.8mmol, 4eq) of anhydrous K2CO3 were added to 500ml of acetonitrile and heated under reflux and stirred overnight. After the reaction was completed, the reaction solution was filtered while hot, the solid was washed with acetonitrile and the filtrate was concentrated. The concentrate was chromatographed on a silica gel column to obtain 15.12g (73%, 14.4mmol) of the target compound Int.3 with a purity of 98.7%.

[0203] LC-MS(ESI+): m / z=1050.8(M+H) + .

[0204] 1H NMR (400 MHz, CDCl3) δ 6.70 (s, 2H), 4.20 (s, 2H), 4.01 – 3.93 (m,9H), 3.88 – 3.80 (m, 5H), 2.97 – 2.90 (m, 4H), 2.84 – 2.76 (m, 2H), 2.74 –2.68 (m, 2H), 1.41 (s, 27H), 1.39 (s, 27H).

[0205] Synthesis of compound Int 4:

[0206] Add 14.00g (13.3mmol) of Int.3 and 70ml of TFA into 500ml of dichloromethane, heat the reaction solution under reflux and stir for 5-8h. After the reaction is completed, concentrate the reaction solution and evaporate it with dichloromethane solution for 3 times (200ml each time). The obtained concentrate is solidified and crystallized with ethanol to obtain 7.99g (84%, 11.2mmol) of the target compound Int.4 with a purity of 97.5%.

[0207] LC-MS(ESI+): m / z=714.8(M+H) + .

[0208] 1 H NMR (400 MHz, CD3OD) δ 6.70 (s, 2H), 4.09 (s, 2H), 4.04 (s, 1H), 4.01 (s, 1H), 3.98 – 3.85 (m, 9H), 3.82 (s, 3H), 2.95 – 2.87 (m, 4H), 2.83 –2.78 (m, 2H), 2.72 – 2.65 (m, 2H).

[0209] Synthesis of Complex X:

[0210] 7.50 g (10.5 mmol, 1 eq) of Int.4 was dissolved in 200 ml of water, the pH was adjusted to 6, 2.10 g (5.8 mmol, 0.55 eq) of Gd2O3 was added to the solution, and the reaction solution was heated to 60°C for 8 hours. The reaction solution was concentrated and solidified and crystallized with ethanol to obtain 7.03 g (77%, 8.1 mmol) of the target compound X with a purity of 98.0%.

[0211] Example 18 Synthesis of Complex Y

[0212]

[0213] The preparation method is the same as the preparation method of complex X in Example 13, except that Int.1 in Example 13 is replaced by Int.5 to obtain complex Y with a purity of 96.4%.

[0214] LC-MS(ESI+): m / z=838.9(M+H) + .

[0215] Comparative Example 1 Synthesis of Chelate 1-Gadopiclenol

[0216]

[0217] The chelate 1-Gadopiclenol was prepared according to the preparation method of Example 2 in patent CN101305006A as comparative example 1 of the present invention, and purified by reverse phase preparative chromatography and dried to obtain the target comparative example 1 compound with a purity of 97.5%. The structural identification was consistent, and the LC-MS (ESI+) of the main product was: m / z=971.1 (M+H) + , that is, the molecular weight of the main product is 970.1. The chemical structure of the product is the same as that shown in Comparative Example 1 above.

[0218] Effect Test Example 1 Relaxivity Measurement at 3.0 T

[0219] Relaxivity measurements at 3.0 T were performed by a whole-body 3.0 T MRI scanner using a knee coil. The sample tubes were placed in tubes 4 and 5 of 3 columns in a plastic holder in a box filled with water, and the temperature was adjusted to 37°C.

[0220] For the MRI sequence, the shortest possible echo time (TE) of 7.46 milliseconds was used. The inversion times were selected to optimize the sequence to measure T1 values ​​corresponding to the estimated T1 range of all relaxation times of the contrast-containing solution. The following inversion times (TI) were used: 50, 100, 150, 200, 300, 500, 700, 1000, 1400, 2100, 3200 and 4500 milliseconds. After registration of the last echo, the sequence was run at a constant relaxation delay of 3.4 seconds (the range of variable TR was 3450-7900 milliseconds).

[0221] Relaxivity was assessed using three different concentrations of each compound (3 concentrations ranging from 0.05 to 2 mM).

[0222] The T1 relaxation times of the example compounds were measured in water and human plasma. Human plasma preparation: For each experiment, fresh blood was taken from volunteers using a 10 mL citrate tube. The 10 mL citrate tube was carefully inverted ten times to mix the blood and anticoagulant and centrifuged at room temperature for 15 minutes.

[0223] The relaxivity r1 was calculated based on the relaxation time T1 measured in water and plasma:

[0224]

[0225] Wherein “T1 intrinsic” is the relaxation time corresponding to the blank solvent, and “[contrast agent]” represents the concentration of the compound standardized to gadolinium. The results are shown in Table 1.

[0226] Table 1 Relaxivities in water and human plasma at 3.0T, 37°C (normalized to Gd) [L / mmol / s]

[0227]

[0228] From the results in the above table, it can be seen that the relaxivities of the complexes 1-5, 8-9, 11-15 and 18-19 prepared by the present invention are significantly stronger than 1-Gadopiclenol, which proves that the complexes 1-5, 8-9, 11-15 and 18-19 of the present invention have better angiographic effects; in particular, the relaxivities of complexes 5, 8 and 9 are more prominent, and the angiographic effects are more advantageous.

[0229] Effect Test Example 2 Chelation Stability Measurement in Tris-HCl Buffer

[0230] The complex prepared in the present example and the complex prepared in comparative example 1 were dissolved in 10 mM Tris-HCl buffer (pH 7.4) to a final concentration of 5 mmol Gd / L. An aliquot was removed and the rest of the clear and colorless solution was autoclaved at 121°C for 20 min; after autoclaving, the solution was still clear and colorless. The Gd released from the chelate before and after autoclaving was determined by HPLC-ICP-MS. 3+ The amount of Gd before and after autoclaving was monitored by ICP-MS. 3+ The results are shown in the following table:

[0231] Table 2 Gd in solution 3+ The release amount

[0232]

[0233] Note: The limit of quantification is 0.1% of the total amount of gadolinium.

[0234] From the results in the above table, it can be seen that the stability of complexes 1, 5, 8, 9, and 15 prepared by the present invention in Tris-HCl buffer is better than that of 1-Gadopiclenol. In the detection system of complexes 1, 5, 8, 9, and 15, no chromatographic changes before and after high-pressure sterilization were detected, indicating that the complex prepared by the present invention is stable during the high-pressure sterilization operation. 3+The release amounts were all less than 0.1%, which was below the limit of quantification, and the stability was better than that of 1-Gadopiclenol.

[0235] Effect Test Example 3 Measurement of Chelation Stability in Plasma

[0236] The complex prepared in the present embodiment and the complex prepared in comparative example 1 were dissolved in human plasma at 1 mmol Gd / L. 0.1 mmol / L gadolinium chloride (GdCl3) was dissolved in human plasma as the released Gd 3+ The plasma samples were incubated at 37°C in a 5% CO2 atmosphere for 15 days, maintaining the pH at 7.4. Aliquots were taken at the beginning and end of the incubation, and the Gd released from the chelate was determined by HPLC-ICP-MS. 3+ The amount of Gd was specifically monitored by ICP-MS, and the chromatogram changes of the intensity of the monitored Gd were evaluated by peak area analysis. The results are shown in the following table:

[0237] Table 3 Gd in plasma 3+ The release amount

[0238]

[0239] Note: The limit of quantification is 0.1% of the total amount of gadolinium

[0240] From the results in the above table, it can be seen that no chromatographic changes before and after the measurement were detected in the detection system of complexes 1, 5, 8, 9, and 15 prepared by the present invention, indicating that there is no free Gd in the system. 3+ ions, indicating that compounds 1, 5, 8, 9, and 15 are stable in plasma. 3+ The release amount is less than 0.1%, which is below the limit of quantification. The stability of the complex in plasma is better than that of 1-Gadopiclenol.

[0241] Effect Test Example 4 Water Solubility Measurement

[0242] The water solubility of the compound was determined in 0.5 mL of buffer solution (10 mM Tris-HCl) at room temperature (20 °C) in a microcentrifuge tube. Measurement method: The solid compound was gradually added to the buffer solution, the suspension was mixed using an oscillator, and treated in an ultrasonic bath for 5 min until insoluble matter appeared. The solubility of the compound was calculated, which refers to the mass of solute dissolved in 100 g of solvent when the solid substance reaches saturation at a certain temperature. The measurement results are shown in the following table:

[0243] Table 4 Water solubility

[0244]

[0245] From the results in the above table, it can be seen that the solubility of complexes 1, 5, 8, 9 and 15 prepared by the present invention is greater than 1000 mg / 100 ml, and can be used as contrast agents for intravenous administration.

[0246] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit it. Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art should understand that they can still modify the technical solutions described in the aforementioned embodiments, or replace some or all of the technical features therein with equivalents. However, these modifications or replacements do not cause the essence of the corresponding technical solutions to deviate from the scope of the technical solutions of the embodiments of the present invention.

Claims

1. A metal complex having a structure shown in formula L-II-1: (L-Ⅱ-1) Wherein, R0 is selected from H; R5 is selected from H, -CH3 or -CH2-CH2OH; R4 is or , m is selected from 0, 1 or 4. When m is 0, it means that the -CHOH- group does not exist; R8, R9, R 10 are each independently selected from H or -CH2OH, and R8, R9, R 10 Two of them are -CH2OH, or R8, R9, R 10 All are -CH2OH.

2. The metal complex according to claim 1, characterized in that The metal complex has the following structural formula: 、 、 、 、 、 、 。 3. A method for preparing the metal complex according to any one of claims 1 to 2, comprising: ; Wherein, G is selected from -OCH3; R0 is selected from H; R5 is selected from H, -CH3 or -CH2-CH2OH; R4 is or , m is selected from 0, 1 or 4. When m is 0, it means that the -CHOH- group does not exist; R8, R9, R 10 are each independently selected from H or -CH2OH, and R8, R9, R 10 Two of them are -CH2OH, or R8, R9, R 10 All are -CH2OH; As shown in the above formula, compound M2 is dissolved in water, the pH is adjusted to 6, compound M1 and dioxane are added, HOBT and EDCI are added under stirring, the pH of the reaction solution is adjusted to 6, the reaction is carried out for 24 hours, and the mixture is concentrated under reduced pressure. An equal volume of ethanol and ether are added to disperse the solid, and the mixture is filtered and separated by reverse phase preparative chromatography to obtain metal complex M.

4. A pharmaceutical composition comprising the metal complex according to any one of claims 1 to 2, and a pharmaceutically acceptable adjuvant or auxiliary agent.

5. Use of the metal complex according to any one of claims 1 to 2 or the pharmaceutical composition according to claim 4 in the preparation of a contrast agent for magnetic resonance imaging.